Diaceutics (LON:DXRX) Sets New 52-Week High - Here's Why

Key Points

• Diaceutics PLC shares reached a new 52-week high at GBX 151.50 ($2.05), closing at GBX 150 ($2.03) with over 1 million shares traded.
• Market analysts show a mixed outlook with Royal Bank Of Canada lowering its price target to GBX 185, while Canaccord Genuity maintains a buy rating with a target of GBX 180.
• The company boasts a significant market cap of £126.82 million and a current ratio of 4.85, indicating a strong financial position.

Diaceutics PLC (LON:DXRX - Get Free Report) shares hit a new 52-week high on Friday . The company traded as high as GBX 151.50 ($2.05) and last traded at GBX 150 ($2.03), with a volume of 1011205 shares changing hands. The stock had previously closed at GBX 147 ($1.99).

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DXRX. Royal Bank Of Canada decreased their price objective on shares of Diaceutics from GBX 195 to GBX 185 and set an "outperform" rating for the company in a research report on Thursday, July 10th. Canaccord Genuity Group restated a "buy" rating and issued a GBX 180 price objective on shares of Diaceutics in a report on Tuesday, July 22nd. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of GBX 175.

Diaceutics Stock Up 2.0%

The firm's 50-day moving average price is GBX 136.13 and its 200-day moving average price is GBX 127.71. The company has a market cap of £126.82 million, a price-to-earnings ratio of -7,425.74 and a beta of 0.58. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.85 and a quick ratio of 9.92.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.